Related references
Note: Only part of the references are listed.Molecular and morphological changes induced by ivosidenib correlate with efficacy in mutant-IDH1 cholangiocarcinoma
Elia Aguado-Fraile et al.
FUTURE ONCOLOGY (2021)
Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials
Robert C. Doebele et al.
LANCET ONCOLOGY (2020)
Ivosidenib in IDH1-mutant, chemotherapy-refractory Croatia& cholangiocarcinoma (ClarlDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study
Ghassan K. Abou-Alfa et al.
LANCET ONCOLOGY (2020)
Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study
Ghassan K. Abou-Alfa et al.
LANCET ONCOLOGY (2020)
Cholangiocarcinoma 2020: the next horizon in mechanisms and management
Jesus M. Banales et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2020)
Benefit of second-line systemic chemotherapy for advanced biliary tract cancer: A propensity score analysis
Florian Moik et al.
SCIENTIFIC REPORTS (2019)
Combination versus mono-therapy as salvage treatment for advanced biliary tract cancer: A comprehensive meta-analysis of published data
Jie Ying et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2019)
Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children
A. Drilon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant Cancers
Janeta Popovici-Muller et al.
ACS MEDICINAL CHEMISTRY LETTERS (2018)
Forty-Year Trends in Cholangiocarcinoma Incidence in the US: Intrahepatic Disease on the Rise
Supriya K. Saha et al.
ONCOLOGIST (2016)
Systemic Therapy of Cholangiocarcinoma
Ruben R. Plentz et al.
VISCERAL MEDICINE (2016)
Second-line chemotherapy for advanced biliary tract cancer after failure of the gemcitabine-platinum combination: A large multicenter study by the Association des Gastro-Enterologues Oncologues
Bertrand Brieau et al.
CANCER (2015)
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
D. T. Le et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Second-line chemotherapy in advanced biliary cancer: a systematic review
A. Lamarca et al.
ANNALS OF ONCOLOGY (2014)
Mutant IDH inhibits HNF-4α to block hepatocyte differentiation and promote biliary cancer
Supriya K. Saha et al.
NATURE (2014)
被撤回的出版物: World Medical Association Declaration of Helsinki Ethical Principles for Medical Research Involving Human Subjects (Retracted article. See vol. 135, pg. 2149, 2021)
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2013)
Adjusting overall survival for treatment switches: commonly used methods and practical application
Claire Watkins et al.
PHARMACEUTICAL STATISTICS (2013)
Chemotherapy for cholangiocarcinoma: An update
Natalia Ramirez-Merino et al.
WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY (2013)
Assessing methods for dealing with treatment switching in randomised controlled trials: a simulation study
James P. Morden et al.
BMC MEDICAL RESEARCH METHODOLOGY (2011)
Development of a questionnaire (EORTC module) to measure quality of life in patients with cholangiocarcinoma and gallbladder cancer, the EORTC QLQ-BIL21
E. Friend et al.
BRITISH JOURNAL OF CANCER (2011)
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer.
Juan Valle et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Share Paper
